In a joint letter, the ACR urges Congress to undergo comprehensive reform of the Medicare payment system and seek long-term payment solutions that will allow clinicians to continue to care for Medicare patients.
FDA Revokes Emergency Use Authorization for Evusheld
The Food & Drug Administration announced Jan. 26 that tixagevimab/cilgavimab (Evusheld) is no longer authorized for use in the U.S. The decision was based on new data suggesting that the treatment is unlikely to be active against the most common current SARS-CoV-2 variants.
How Long Should Methotrexate Be Held Following Seasonal Vaccinations?
Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA.
First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles
After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.
Rheumatology Online: Disseminating the State of the Art on Social Media at ACR Convergence 2022
PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging with Social Media at Conferences Jean Liew, MD, MS, assistant professor of medicine in the Section…
Key Facts on Billing Drug Wastage
The ACR has compiled guidelines and tips on how to use the JW modifier and correctly bill Medicare for discarded drugs and biologicals. This modifier can be applied only to unused amounts from a single-dose vial or package.
CMS Announces Timeline for Drug Negotiations
This month, the CMS will begin steps to develop a drug pricing negotiation process as allowed by the Inflation Reduction Act. The ACR plans to participate in public comment opportunities.
Rheumatology Association of Iowa Supports Members & Advocates for Patients
One of the newer state rheumatology organizations, the Rheumatology Association of Iowa, brings together rheumatology professionals, offering connections to fill rural care needs and advocate for policies that support patient care. The organization’s 9th annual meeting will be Feb. 24–25.
A World of Difference: Updates from the Global Rheumatology Summit
The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.
Dr. Michelle Petri: A Guiding Light for Patients with Lupus
Systemic lupus erythematosus (SLE) affects a substantial number of patients worldwide, with an estimated prevalence in North America of 241 per 100,000 people.1 The morbidity and mortality associated with the condition can be significant, and thus research on this disease continues to be of utmost importance. The story of one of the world’s leading experts…
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 805
- Next Page »